
Entrada Therapeutics, Inc. (NASDAQ:TRDA – Free Report) – HC Wainwright increased their FY2026 earnings per share (EPS) estimates for Entrada Therapeutics in a research report issued on Thursday, November 12th. HC Wainwright analyst R. Selvaraju now anticipates that the company will post earnings of ($3.99) per share for the year, up from their previous forecast of ($4.19). HC Wainwright has a “Neutral” rating on the stock. The consensus estimate for Entrada Therapeutics’ current full-year earnings is ($4.12) per share. HC Wainwright also issued estimates for Entrada Therapeutics’ Q4 2026 earnings at ($1.09) EPS, Q1 2027 earnings at ($0.83) EPS, Q2 2027 earnings at ($0.75) EPS, Q3 2027 earnings at ($0.82) EPS, Q4 2027 earnings at ($0.89) EPS and FY2027 earnings at ($3.29) EPS.
A number of other research analysts have also recently commented on the stock. Weiss Ratings upgraded shares of Entrada Therapeutics from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Wednesday, November 4th. UBS Group reissued a “neutral” rating on shares of Entrada Therapeutics in a research note on Monday, October 19th. Wall Street Zen upgraded shares of Entrada Therapeutics from a “sell” rating to a “hold” rating in a report on Monday, November 9th. Finally, Roth Capital restated a “buy” rating and issued a $11.00 price objective on shares of Entrada Therapeutics in a report on Wednesday, August 12th. Four investment analysts have rated the stock with a Buy rating, two have given a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, the company currently has a consensus rating of “Hold” and a consensus target price of $17.75.
View Our Latest Research Report on Entrada Therapeutics
Entrada Therapeutics Stock Performance
NASDAQ:TRDA opened at $4.96 on Monday. The business has a 50 day moving average of $5.50 and a 200 day moving average of $8.36. Entrada Therapeutics has a 1-year low of $4.11 and a 1-year high of $16.45.
Entrada Therapeutics (NASDAQ:TRDA – Get Free Report) last announced its quarterly earnings data on Thursday, November 5th. The company reported ($0.94) EPS for the quarter, beating the consensus estimate of ($1.01) by $0.07. The firm had revenue of $0.91 million for the quarter, compared to analyst estimates of $2.30 million. Entrada Therapeutics had a negative return on equity of 64.00% and a negative net margin of 4,057.98%.
Insider Buying and Selling
In other news, major shareholder Bioventures 2018 L.P. Mpm sold 192,500 shares of Entrada Therapeutics stock in a transaction that occurred on Tuesday, September 8th. The shares were sold at an average price of $7.41, for a total transaction of $1,426,425.00. Following the completion of the transaction, the insider directly owned 3,913,952 shares in the company, valued at approximately $29,002,384.32. This trade represents a 4.69% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, major shareholder Bioventures 2014 L.P. Mpm sold 26,522 shares of Entrada Therapeutics stock in a transaction that occurred on Tuesday, August 25th. The shares were sold at an average price of $7.54, for a total transaction of $199,975.88. Following the transaction, the insider owned 4,332,917 shares of the company’s stock, valued at $32,670,194.18. The trade was a 0.61% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders have sold 495,947 shares of company stock valued at $3,600,470 in the last ninety days. Insiders own 9.49% of the company’s stock.
Institutional Inflows and Outflows
Institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Goldman Sachs Group Inc. grew its holdings in shares of Entrada Therapeutics by 68.1% during the third quarter. Goldman Sachs Group Inc. now owns 298,172 shares of the company’s stock valued at $1,893,000 after buying an additional 120,829 shares during the last quarter. Jump Financial LLC increased its position in shares of Entrada Therapeutics by 241.7% during the third quarter. Jump Financial LLC now owns 82,259 shares of the company’s stock valued at $522,000 after acquiring an additional 58,187 shares in the last quarter. Empowered Funds LLC bought a new stake in shares of Entrada Therapeutics during the third quarter valued at approximately $283,000. Russell Investments Group Ltd. raised its holdings in Entrada Therapeutics by 14.2% in the 3rd quarter. Russell Investments Group Ltd. now owns 26,776 shares of the company’s stock worth $170,000 after acquiring an additional 3,326 shares during the last quarter. Finally, Allspring Global Investments Holdings LLC raised its holdings in Entrada Therapeutics by 24.7% in the 3rd quarter. Allspring Global Investments Holdings LLC now owns 116,596 shares of the company’s stock worth $740,000 after acquiring an additional 23,058 shares during the last quarter. Institutional investors own 86.39% of the company’s stock.
Entrada Therapeutics Company Profile
Entrada Therapeutics is a biotechnology company focused on developing medicines that deliver therapeutic molecules into cells. Founded in 2016 and based in Boston, Massachusetts, the company developed its Endosomal Escape Vehicle (EEV) platform to help move drug cargo across cellular membranes and reach intracellular targets. The company’s research centers on its EEV-based oligonucleotide medicines, including programs designed to address genetic causes of neuromuscular diseases. Its development work includes candidates intended to alter RNA processing for Duchenne muscular dystrophy, with programs targeting different genetic subgroups of the disease.
Featured Stories
- Five stocks we like better than Entrada Therapeutics
- NVIDIA’s Turbulence Could Have Ripple Effects Across Quantum Computing
- Banking on AI: Can Upstart’s New Bank Plan Turn Its Stock Around?
- Amazon’s Black Friday Rush Could Kick Off a Holiday Season That Defines Its Year
- The Next Nuclear Opportunity May Be in Fuel, Not Reactors: 3 Stocks to Watch
Receive News & Ratings for Entrada Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Entrada Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
